- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 Pathogenesis of AMD
- •1.2.1 Oxidative Damage
- •1.2.2 Lipofuscin Accumulation
- •1.2.4 Complement Mutations
- •1.2.5 Mitochondrial Damage
- •1.2.6 DICER 1
- •1.3 Treatment
- •1.3.1 Antioxidants
- •1.3.2 Visual Cycle Modulators
- •1.3.4 Neurotrophic Agents
- •1.3.5 Antiangiogenic Agents
- •1.3.5.1 Intracellular Angiogenic Factor Production
- •1.3.5.2 Extracellular Angiogenic Factors
- •1.3.6 Endothelial Cell Receptor Binding
- •1.3.7 Endothelial Cell Activation
- •1.3.8 Endothelial Cell Proliferation
- •1.3.9 Endothelial Cell Directional Migration
- •1.3.10 Extracellular Matrix Remodeling
- •1.3.11 Tube Formation
- •1.3.11.1 Loop Formation (Arteriovenous Differentiation)
- •1.3.11.2 Vascular Stabilization
- •1.4 Combination Therapy
- •1.5 Conclusions
- •References
- •2.1 Introduction
- •2.1.1 Complement Pathways
- •2.1.2 Oxidative Stress
- •2.3.1 The Mouse CNV Model
- •2.3.2 RPE Monolayers
- •2.3.3 Concept
- •2.5 Summary and Outlook
- •References
- •3.1 Introduction
- •3.2.1 Advanced Glycation End Products
- •3.2.2 Carboxyethylpyrrole
- •3.2.3 Oxidation Products of Lipofuscin
- •3.3 Summary and Conclusions
- •References
- •4.1 Introduction
- •4.2 Oxidative Stress and AMD
- •4.2.1 Basic Concepts on Oxidative Stress
- •4.2.2 Oxidative Stress in AMD
- •4.3 Malondialdehyde in AMD
- •4.3.1 Lipid Peroxidation and Malondialdehyde
- •4.3.2 Materials and Methods
- •4.3.2.1 RPE Cell Culture
- •4.3.2.2 Patients
- •4.3.2.3 MDA Assay
- •4.3.3 MDA Levels in Cultured RPE Cells and in Patients with AMD
- •4.4 Summary and Conclusions
- •References
- •5.1 Introduction
- •5.2 The Origin and Housing of RPE Lipofuscin
- •5.3 Bisretinoid Constituents of RPE Lipofuscin
- •5.3.1 A2E, Isomers and Precursors
- •5.3.4 Photooxidized Forms of Bisretinoid Pigments
- •5.4 Photoreactivity of RPE Lipofuscin
- •5.5 Photooxidation of RPE Bisretinoids
- •5.6 Bisretinoid Photodegradation
- •5.7 Potential for Cell and Tissue Damage
- •5.9 A Role for Antioxidants
- •5.10 Conclusions
- •References
- •6.1 Introduction
- •6.1.1 RPE Lipofuscin Accumulation with Age and Relation to AMD
- •6.1.2 Known Chromophores Found in RPE Lipofuscin and the Mechanism of Damage
- •6.1.3 Formation of Higher Molecular Weight Material
- •6.1.4 Current Studies and Possible Structures of Higher Molecular Weight Products
- •6.1.4.1 Lipofuscin Extracts
- •6.1.4.3 Esters and Aldehydes
- •6.2 Conclusions
- •References
- •7.2 DHA in Photoreceptor Cells
- •7.3 Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
- •7.5 Neurotrophins Trigger the Synthesis and Polarized Secretion of Neuroprotectin D1 from Human RPE Cells
- •7.6 Photoreceptor Outer Segment Phagocytosis Induces RPE Cell Survival Signaling with Associated Synthesis of NPD1 During Oxidative Stress
- •References
- •8.1 Introduction
- •8.2.1 Subcellular Localization
- •8.2.2 Expression Levels in the Retina
- •8.4.3 Regulation of RDH12 Expression and Activity During Chronic and Acute Stress
- •8.5 RDH12 and Leber Congenital Amaurosis
- •8.5.1 Inactivating Mutations of RDH12
- •8.5.2 Loss of Which RDH12 Function Induces LCA?
- •8.6 Summary and Conclusions
- •References
- •9.1 Introduction
- •9.2 GSH Metabolism: General Principles
- •9.2.2 Role of Mitochondrial GSH in Protection
- •9.2.3 GSH as a ROS Scavenger
- •9.2.4 GSH Distribution in the Retina and RPE in Health and Disease
- •9.5 Future Perspectives
- •References
- •10.1 Introduction
- •10.2 Mitochondria
- •10.2.1 Mitochondrial Biogenesis and Maintenance
- •10.2.2 Mitochondrial Removal and Degradation
- •10.3 Mitochondria and Reactive Oxygen Species
- •10.3.1 Reactive Oxygen and Nitrogen Species (ROS and RNS)
- •10.3.2 Mitochondria are a Major Source of Intracellular ROS
- •10.3.3 Other Sources of ROS in the Retina
- •10.4 The Mitochondrial Genome
- •10.4.1 Susceptibility of Mitochondrial DNA to Oxidative Stress
- •10.4.2 Mitochondrial DNA Damage
- •10.4.3 Mitochondrial DNA Repair Pathways
- •10.4.4 The Mitochondrial Base Excision Repair (mtBER) Pathway
- •10.4.6 Other Mitochondrial DNA Repair Pathways
- •10.4.6.2 Mismatch Repair (MMR)
- •10.4.6.3 Translesion Synthesis (TLS) and Damage Tolerance
- •10.4.6.4 Nucleotide Excision Repair (NER)
- •10.4.7 Intramitochondrial Localization of DNA Repair Proteins
- •10.4.8 mtDNA Damage Sensing and Signaling
- •10.4.9 Import of Nuclear Encoded DNA Repair Enzymes into the Mitochondria
- •10.5 Mitochondrial DNA Damage/Repair in the Retina and RPE
- •10.5.1 Mitochondrial DNA Damage/Repair in the RPE
- •10.5.2 DNA Repair and the Adaptive Response in the RPE
- •10.6 Pathologies Associated with Mitochondrial Dysfunction and Oxidative Stress in the Retina
- •10.6.2 Diabetic Retinopathy
- •10.6.3 Glaucoma
- •10.6.4 Uveitis
- •10.7 Pathologies Associated with Inherited Mitochondrial Disorders
- •10.8 Potential Therapeutic Options for Targeting Mitochondrial DNA Damage
- •10.8.1 Mitochondrial Biogenesis
- •10.8.2 Enhancing mtDNA Repair
- •10.8.3 Antioxidants
- •10.8.4 Autophagy
- •10.9 Conclusion
- •References
- •11.1 Introduction
- •11.2 ER Function in Normal Physiology
- •11.2.1 Major Roles of Rough ER (RER) and Smooth ER (SER)
- •11.2.2 ER and Oxidative Protein Folding
- •11.2.3 ER Resident Proteins
- •11.2.4 Potential Threat to ER Function in RPE
- •11.3 ER Response to Oxidative Stress in RPE
- •11.3.2 Initiation of UPR to Alleviate ER Burden
- •11.4 Chronic ER Stress and Oxidative Stress in the Vicious Cycle of Apoptosis Induction
- •11.5 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 Iron Homeostasis
- •12.2.1 General Iron Homeostasis
- •12.2.2 Iron Import into the Retina
- •12.2.2.1 Transferrin Mediated Transport
- •12.2.2.3 Dexras
- •12.2.3 Iron Storage
- •12.2.3.1 Ferritin
- •12.2.3.2 Mitochondrial Ferritin
- •12.2.4 Iron Export
- •12.2.4.1 Ceruloplasmin
- •12.2.4.2 Hephaestin
- •12.2.4.3 Ferroportin and Hepcidin
- •12.3 Disruption of Iron Homeostasis and Oxidative Damage
- •12.4 Retinal Disorders Resulting from Abnormal Retinal Iron Metabolism
- •12.4.2 Aceruloplasminemia
- •12.4.3 Hemochromatosis
- •12.4.4 Friedreich’s Ataxia
- •12.4.6 Siderosis
- •12.4.7 Subretinal Hemorrhage
- •12.5 Potential Therapeutics
- •References
- •13.1 Vascular Endothelial Growth Factor and Its Functions in the Retina
- •13.1.1 VEGF Isoforms
- •13.1.2 VEGF Functions
- •13.1.3 Cells Secreting VEGF in the Retina
- •13.1.3.1 Retinal Pigment Epithelium
- •13.1.3.2 Müller Cells
- •13.1.3.3 Astrocytes
- •13.1.3.4 Pericytes
- •13.1.4 VEGF Receptors and VEGF Induced Signal Transduction
- •13.1.4.1 VEGF Receptors
- •VEGFR-1
- •VEGFR-2
- •Neuropilin
- •Heparan Sulfate Proteoglycan
- •13.2 Regulation of VEGF Expression
- •13.2.1 Transcriptional Regulation
- •13.2.2 Translational Regulation
- •13.2.3 Hypoxia Induced VEGF Regulation
- •13.2.4 Posttranslational Regulation
- •13.2.5 Autocrine VEGF Regulation
- •13.2.6 Pathological VEGF Production
- •13.2.6.1 Hyperglycemia
- •13.2.6.2 Oxidative Stress
- •13.2.6.3 Cytokines
- •13.2.6.4 Endoplasmic Reticulum
- •13.2.6.5 Additional Factors
- •13.3.1 Pegaptanib
- •13.3.2 Bevacizumab and Ranibizumab
- •13.3.4 siRNA
- •13.3.5 Small Molecule Tryrosine Kinase Inhibitors
- •13.3.6 Other Inhibitors
- •13.4.2 Interaction of VEGF Antagonists with Antiangiogenic VEGFxxxb
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2 NADPH Oxidase and Redox Signaling
- •14.3 Expression of NADPH Oxidase Subunit p22phox in the Retina
- •14.4 NADPH Oxidase and Choroidal Neovascularization
- •14.5 Implication and Therapeutic Potential of NADPH Oxidase in Development of CNV
- •14.6 Summary and Future Perspective
- •References
- •15.1 Introduction
- •15.2 Aging
- •15.3 Deposition and Formation of Oxidized LDL
- •15.6 Treatments for AMD
- •15.7 Conclusions
- •References
- •16.1 Introduction
- •16.2 HGF and Its Receptor (MET)
- •16.2.1 Production and Secretion of HGF
- •16.2.2 MET and Biological Effects of HGF
- •16.2.3 Signaling Pathways of HGF
- •16.2.4 HGF and MET in Disease States
- •16.4 HGF Protects RPE Cells from Oxidative Stress
- •16.4.1 HGF and RPE Cells
- •16.4.2 HGF Promotes Cell Survival
- •16.4.3 HGF Protects Cells from Oxidative Stress
- •16.4.4 HGF Protects RPE Cells from Hydrogen Peroxide
- •16.4.5 HGF Protects RPE Cells Against Ceramide Damage
- •16.4.6 HGF Protects RPE Cells from Glutathione Depletion
- •References
- •17.1 Introduction
- •17.2.1 Fundoscopy
- •17.2.2 Histology
- •17.2.3 Ultrastructure
- •17.3.1 Lipofuscin (A2E)
- •17.3.3 HtrA2/Omi
- •References
- •18.1 Introduction
- •18.2 Systemic Markers of Oxidative Stress
- •18.2.1 Redox Status
- •18.2.2 DNA Damage
- •18.2.4 Lipid Peroxidation
- •18.3 Defenses Against Oxidative Stress
- •18.3.1 Antioxidants
- •18.3.2 Antioxidant Enzymes
- •18.4 Oxidative Stress and Genetics
- •18.4.1 Antioxidant Enzyme Polymorphisms
- •18.5 Environmental Exposures and Oxidative Stress
- •18.5.1 Smoking
- •18.5.2 Light Exposure
- •18.6 AMD Treatments and Oxidative Stress
- •18.8 Summary and Conclusions
- •References
- •19.1 Characteristics of Cerium Oxide Nanoparticles
- •19.3 Mechanism of Nanoceria Uptake, Internalization, and Localization in the Cell
- •19.4 Biological Effect, Functional Mechanism, and Applications
- •19.4.1 Bacteria
- •19.4.2 Plants
- •19.4.3 Medical Usage
- •19.4.3.1 Radioprotectants
- •19.4.3.2 Burn Treatment
- •19.4.4 Medical Imaging
- •19.5 Stability of Nanoceria Under storage Conditions and Its Longevity in the Cell In Vivo
- •19.6 Oxidative Damage Results in Neurodegeneration
- •19.7.1 Prolong Cellular Life Span
- •19.7.2 Cardioprotection
- •19.8 Treatment of Ocular Disorders
- •19.8.1 Methodology
- •19.8.2 Prevention of Light Damage and Rescue of Retinal Function
- •19.8.3 Treatment of Degenerative Ocular Diseases
- •19.8.4 Treatment of Ocular Neovascular Diseases
- •19.9 Toxicity and Environmental Impacts
- •19.10 Conclusion and Future Directions
- •References
- •20.1 Introduction
- •20.2 Retinal Progenitor Cells (RPCs) Are Multipotential
- •20.4 Therapeutic Strategies for Repair and Regeneration of Retinal Cells: Repair of the RPE
- •20.5 Challenges for RPE Stem Cell Therapy
- •20.6 Characterization of RPE-Like Cells Derived from BMDCs
- •20.7 BMDCs Differentiate into Retinal Cells
- •20.8 Summary and Future of Cell Therapy for Dysfunctional RPE
- •References
- •21.1 Introduction
- •21.2 Carotenoids in Retinal Diseases
- •21.4 Polyphenols or Phenolic Esters in Retinopathies
- •21.4.1 Caffeic Acid Phenethyl Ester
- •21.4.2 Catechin
- •21.4.3 Curcumin
- •21.4.4 Proanthocyanidin
- •21.4.5 Resveratrol
- •21.5.2 Sulforaphane
- •21.6 Vitamins in Retinopathies
- •21.6.1 Vitamin A
- •21.7 Perspectives
- •References
- •22.1 Introduction
- •22.1.1 Neuroprotection as a Strategy for Retinal Degenerative Disease
- •22.2.2 Putative Mechanisms of CNS Neuroprotection
- •22.3.9 Conclusion
- •22.4 Mechanisms of Retinal Protection
- •22.4.1 Insights from In Vitro Models
- •22.5.1 Background to the Disease and the Associated Preclinical Data
- •22.5.2 Overview of the Clinical Development Program
- •References
- •23.1 Introduction
- •23.2 Pathogenesis
- •23.4 Pegaptanib
- •23.5 Bevacizumab
- •23.6 Ranibizumab
- •23.7.1 Ranibizumab
- •23.7.2 Bevacizumab
- •23.8 Comparison of AMD Treatment Trials (CATT)
- •23.9 Management of Nonresponders
- •23.11 Conclusion
- •References
- •24.1 Introduction
- •24.2 Rationale for Combination Therapy
- •24.3 Supporting Evidence for Combination Therapy
- •24.4 Currently Applied Combination Therapies
- •24.5 Challenges for Combination Therapy
- •References
- •25.1 Human Endothelial Progenitor Cells
- •25.3 Function of EPCs
- •25.3.1 EPCs in Vascular Repair and Neovascularization
- •25.4 EPCs in Diabetes
- •25.4.1 EPC as a Biomarker in Diabetes
- •25.4.1.1 EPC Dysfunction in Diabetes
- •25.4.1.2 Oxidative Stress and EPC Dysfunction in Diabetes
- •25.4.1.3 Therapeutic Angiogenesis by EPCs in Diabetic Retinopathy
- •25.5 Conclusion
- •References
- •26.1 Introduction
- •26.1.1 Nitric Oxide
- •26.1.2 Nitric Oxide Regulation
- •26.1.3 Nitric Oxide in Normal and Pathophysiological Conditions
- •26.2 Retinal Vascular Diseases: The Role of iNOS
- •26.2.1 Nitric Oxide in Diabetic Retinopathy
- •26.2.2 iNOS in Diabetic Retinopathy
- •26.2.2.2 iNOS and Leukocyte Adhesion to Retinal Vessels
- •26.2.2.3 iNOS and Retinal Cell Death
- •26.2.3 Proliferative Retinal Diseases
- •26.2.3.1 iNOS and Proliferative Retinal Diseases
- •26.2.3.2 iNOS and Ocular Neovascularization in Retinal Vascular Diseases
- •26.3 Conclusions
- •References
- •27.1 Introduction
- •27.2 Animal Model
- •27.2.1 LHP Preparation and Injection Procedure
- •27.2.2 Acridine Orange Digital Fluorography
- •27.3 Experimental Results
- •27.3.1 Leukocyte Rolling
- •27.3.2 Accumulated Leukocytes in the Retinal Microcirculation
- •27.3.3 Diameter of Major Retinal Vessels
- •27.3.4 SOD Treatment
- •27.4 Discussion
- •27.5 Conclusions
- •References
- •28.1 Introduction
- •28.1.2 Metabolism and Balance in Generation and Quenching of ROS
- •28.2 Role of Oxygen Concentration on Generation of ROS in the Developing Retina
- •28.3.1 Perinatal Considerations
- •28.3.2 Neonatal Considerations
- •28.3.2.1 Polyunsaturated Fatty Acids in Retina and Brain
- •28.3.2.2 Increased Oxidation
- •28.3.2.3 Reduced Antioxidant Enzyme Systems
- •28.3.3 Environmental Stimuli
- •28.3.3.1 Light
- •28.3.3.2 Oxygen Changes in Development and Prematurity
- •28.3.3.3 Nutrition
- •28.3.3.4 Effect of Blood Transfusions on Oxidative Stress in Prematurity
- •28.4 Evidence from Animal Models
- •28.4.1 Background
- •28.4.2 Effects of Hypoxia on Bioenergetic Oxygen Sensor Mechanisms and Related to ROP
- •28.4.2.2 NADPH Oxidase
- •28.4.2.3 Cytochrome p450 Monooxygenases (CYP)
- •28.4.2.4 eNOS
- •28.4.2.5 Heme Oxygenase
- •28.4.2.6 Metabolic Effects of Hypoxia
- •28.4.3 Laboratory Evidence of Antioxidants on Animal Models of ROP
- •28.5 Clinical Studies of Antioxidants on ROP
- •28.6 Genetics
- •28.7 Summary
- •References
- •29.1 Introduction
- •29.1.1 Oxidative Stress in Glaucoma
- •29.1.2 Oxidative Stress in Diabetic Retinopathy
- •29.1.3 Oxidative Stress in Age Related Macular Degeneration
- •29.1.4 Vascular Endothelial Growth Factor
- •29.1.5 VEGF Mediated Neuroprotection
- •29.1.6 Mechanisms of VEGF Protection Against Oxidative Stress
- •References
- •30.1 Introduction
- •30.1.1 Oxidation and Oxidative Stress
- •30.1.2 Reactive Oxygen Intermediates
- •30.1.3 ROIs and Cellular Retinal Damage
- •30.1.4 Light, Cellular Retinal Damage and AMD
- •30.1.5 Carotenoids
- •30.1.6 Chemistry of Carotenoids: Basic Structural Components
- •30.2 Building Blocks
- •30.3 The Polyene Backbone
- •30.5 Terminal Groups
- •30.5.1 Source of Macular Carotenoids
- •30.5.2 Macular Carotenoids: The Origins of Macular Pigment
- •30.5.3 The Functions of the Macular Carotenoids as Macular Pigment for AMD
- •30.6 Antioxidant Properties
- •30.6.1 The Functions of the Macular Carotenoids as Macular Pigment for Visual Performance
- •References
- •31.1 Introduction
- •31.2 Composition and Distribution
- •31.3 Selective Uptake and Deposition Process of MP
- •31.4 Measurements
- •31.4.1 Heterochromatic Flicker Photometry
- •31.4.4 Resonance Raman Spectroscopy
- •31.5 Antioxidant Mechanism of MP and Its Relation to Retinal Health and Disease
- •31.5.1 Oxidative Stress in Human Retina and the Antioxidant Mechanism of MP
- •31.5.2 MP in Human Eye Health and Disease
- •31.5.2.2 MacTel
- •31.5.2.3 Acuity
- •31.6 Ocular Carotenoid Supplementation Studies
- •31.7 Conclusion
- •References
- •Index
- •About the Authors
6 Age-Related Changes in RPE Lipofuscin Lead to Hydrophobic Polymers |
119 |
|
5x107 |
|
A2E |
|
Complex Mixture |
|
|
|
|
|
|
||
|
4x107 |
|
|
|
|
|
|
3x107 |
|
|
|
|
|
|
2x107 |
OX. A2E |
|
|
|
|
|
|
|
|
|
|
|
(AU) |
1x107 |
|
|
|
|
|
|
|
|
|
|
|
|
Intensity |
0 |
|
|
|
|
|
1.0x105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.0x104 |
|
|
|
|
|
|
6.0x104 |
|
|
|
|
|
|
4.0x104 |
|
|
|
|
|
|
2.0x104 |
|
|
|
|
|
|
0.0 |
|
|
|
|
|
|
0 |
20 |
40 |
60 |
80 |
100 |
Time (min)
Fig. 6.4 The Base Peak Chromatogram from the Folch extract of lipofuscin granules (top) and the corresponding photodiode array chromatogram (bottom) are shown. The chromatogram consists of A2E, oxidized A2E, and a complex mixture of components
has an emission maximum at 620 nm. This is precisely the emission maximum that Delori et al. [24] detects in vivo. The remaining compounds found in RPE lipofuscin consists of relatively hydrophobic components corresponding to derivatized A2E with molecular weights in discrete groups of 800–900, 970–1,080 m/z and above 1,200 m/z regions. These modified components increase the hydrophobicity of A2E and may explain the formation of lipofuscin granules in the RPE. The present study is part of a continuing effort to identify the molecular modifications to the structure of A2E [52, 54] and their mechanism of formation.
6.1.4Current Studies and Possible Structures of Higher Molecular Weight Products
6.1.4.1Lipofuscin Extracts
The mass spectroscopy base peak chromatogram and total absorption from the Folch extract of lipofuscin granules is displayed in Fig. 6.4. The chromatogram consists of A2E, oxidized A2E, and a complex mixture of components. Integration of the peak areas indicated that A2E was approximately 5–10% compared to the
120
Intensity (AU)
1.8x106
1.6x106
1.4x106
1.2x106
1.0x106
8.0x105
6.0x105
4.0x105
2.0x105
0.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
L.S. Murdaugh et al. |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ι |
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
ΙΙ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
862.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
1.4x106 |
|
|
|
|
948.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ΙΙΙ |
|
|
|
|
|
|
ΙΙ |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
1.2x106 |
|
|
|
|
|
|
|
|
1083.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
874.9 |
|
|
|
|
|
||||||||||||||||||||
|
|
|
6 |
|
|
|
927.0 |
|
|
|
|
|
|
|
|
|
|
|
|
1455.0 |
860.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
(AU) |
1.0x10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020.8 |
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
8.0x105 |
|
|
|
|
|
|
|
1081.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
847.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Intensity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
6.0x105 |
|
|
|
|
|
|
|
1277.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1022.9 |
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
1046.9 |
1127 |
|
|
|
|
1310.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
876.9 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
|
4.0x105 |
|
904.9 |
|
|
|
|
|
1189.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
2.0x105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
878.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
0.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
971.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
800 |
1000 |
1200 |
1400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
m/z |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
831.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ι Ι Ι |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400 |
600 |
800 |
1000 |
1200 |
m/z
Fig. 6.5 The mass spectrum of the Folch extract of human lipofuscin at time 62.93 and 86.26 min (inset). Group I, II, and III identify the related clusters of higher molecular weight compounds with mass to charges of approximately 800, 1,000, and 1,400 respectively. The arrow indicates the addition of 14 amu to m/z 847.9
complex mixture. We have assumed that all molecules in the mixture have similar ionization efficiency, since all of the instrumental parameters, flow rate, and solvent composition remained constant. After further analysis of the mass spectral data of compounds that eluted from 50 to 100 min, the chromatogram revealed a series of closely related compounds that appeared to be related by a mass of 14 amu, which could be methylene groups. Figure 6.5 displays a representative mass spectrum of compounds that eluted at approximately 60 min with an inset spectrum of compounds eluting at 80 min. There are three clusters of eluting masses, labeled I, II, and III, eluting in the ranges of 800, 1,000, and 1,400 amu.
To determine if these components were structurally related to A2E, the tandem mass spectroscopy (MS/MS) data were analyzed. The MS/MS spectrum and the total absorption of A2E are displayed in Fig. 6.6a, b respectively. The fragmentation pattern displayed characteristic losses of 150, 174, and 190 from the parent ion mass of 592 amu. These distinctive cleavages are illustrated in Fig. 6.6c. Once identified, these losses were compared to the MS/MS data of the components located within the complex mixture of the lipofuscin sample and all of the material that eluted between 50 and 80 min and approximately 50% of the material between 80 and 110 min had analogous spectra exhibiting fragments with the loss of the same m/z fragments.
Figure 6.7a, b display the MS/MS and absorption spectrum of peak with M+ 858, which is representative of components that eluted at approximately 60 min
a
Intensity (AU)
418.4
4x106
3x106
2x106 |
|
|
|
402.4 |
442.4 |
|
|
|
|
|
|
|
392.4 |
|
486.5 |
|
592.6 |
|
|
|
|
|
|
|
|
|
1x106 |
|
|
|
|
|
|
536.4 |
|
|
|
|
352.3 |
|
|
|
|
|
0 |
250 |
300 |
350 |
400 |
450 |
500 |
550 |
600 |
200 |
||||||||
m/z
b
Relative Absorbance (AU)
1.2x105
1.0x105
8.0x104
6.0x104
4.0x104
2.0x104
0.0 














200 250 300 350 400 450 500 550 600
Wavelength (nm)
Fig. 6.6 (a) The MS/MS scan for A2E identified in the Folch extract of Lipofuscin granules. Peaks corresponding to the mass of 592 with the loss of 106, 150, 174, and 190 are identified. (b) The UV-visible spectrum of A2E. (c) Characteristic cleavages for the fragmentation of A2E
m/z 858 in Lipofuscin
|
a |
|
|
|
|
|
668.6 |
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
1.4x106 |
|
|
|
|
|
857.8 |
|
|
|
|
1.2x106 |
|
|
|
|
|
|
|
|
|
(AU) |
1.0x106 |
|
|
|
|
|
|
|
|
|
8.0x105 |
|
|
|
|
|
|
|
||
|
Intensity |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
683.7 |
|
|
|
|
6.0x105 |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
642.6 |
|
|
|
|
|
4.0x105 |
|
|
|
|
708.7 |
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
2.0x105 |
|
|
|
590.6 |
752.7 |
|
||
|
|
|
414.4 |
|
|
842.7 |
|
|||
|
|
|
|
629.6 |
734.7 |
|
||||
|
|
|
|
311.4 |
|
|
|
|
|
|
|
|
|
0.0 |
|
400 |
|
600 |
|
800 |
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
m/z |
|
|
|
b |
|
|
|
|
|
|
|
|
|
|
|
1.0x106 |
|
|
|
|
|
858 lipofuscin |
|||
|
8.0x105 |
|
|
|
|
|
|
|
||
|
6.0x105 |
|
|
|
|
|
|
|
||
(AU) |
4.0x105 |
|
|
|
|
|
|
|
||
2.0x105 |
|
|
|
|
|
|
|
|||
Absorbance |
|
|
|
|
|
|
|
|||
|
0.0 |
300 |
350 |
400 |
450 |
500 |
550 |
600 |
||
|
250 |
|||||||||
1.4x105 |
|
|
|
|
|
858 Aged A2E |
||||
1.2x105 |
|
|
|
|
|
|||||
Relative |
|
|
|
|
|
|||||
|
|
|
|
|
|
|
||||
1.0x105 |
|
|
|
|
|
|
|
|||
8.0x10 |
4 |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
||
|
6.0x104 |
|
|
|
|
|
|
|
||
|
4.0x104 |
|
|
|
|
|
|
|
||
|
2.0x104 |
|
|
|
|
|
|
|
||
|
|
0.0 |
|
|
|
|
|
|
|
|
|
|
250 |
300 |
350 |
400 |
450 |
500 |
550 |
600 |
|
wavelength (nm)
Fig. 6.7 (a) The MS/MS scan of peak with M+ 858 from lipofuscin sample. Peaks corresponding to the mass of 858 with the loss of 106, 150, 174, and 190 are identified. (b) The UV-visible absorption for the peak with M+ 858 in lipofuscin (top) and aged A2E (bottom). (c) The proposed structure for compound with m/z 858
6 Age-Related Changes in RPE Lipofuscin Lead to Hydrophobic Polymers |
123 |
|||||
c |
|
3 |
9 |
9 |
5 |
|
|
|
4 |
6 |
0 |
3 |
|
|
HO |
6 |
7 |
|
||
|
N |
6 |
|
7 |
|
|
|
|
|
|
|
|
|
4
4
4
3
1
5
590
616
656
682
390
468
Fig. 6.7 (continued)
displayed in Fig. 6.4. Once analyzed, Fig. 6.7a displayed ions with masses of 752, 708, 683, and 668, which correspond to losses of 106, 150, 174, and 190 from the parent ion of 858. The peak with m/z 752 is from the loss of xylene, which is commonly observed in polyene compounds that have more than four conjugated double bonds [58, 59]. The absorption spectra in Fig. 6.7b shows two maxima at 330 and 500 nm in the lipofuscin and aged A2E samples. The proposed structure for this 500 nm absorbing species is displayed in Fig. 6.7c. Previously, Radu et al. reported that the 500 nm absorbing species was A2PE-H2 [60]. However, Fishkin et al. later reported that this absorption was from an all trans retinal dimer conjugated to phosphatidylethanolamine (ATR dimer-PE) [61]. Following the Fishken study, Bui et al. further examined native retinal fluorophores involved in the formation of A2E including the 500 nm absorbing species. Based on the absorption and mass spectra, this study concluded that A2E-H2 is not only a precursor to the synthesis of A2E but is also the compound responsible for the 500 nm absorbing species in lipofuscin [62]. However, the fragmentation pattern and absorption spectrum reported here suggests that the 500 nm absorbing species is an A2E derived higher molecular weight product.
The components that eluted with masses in the range of 1,000 and 1,400 amu were analyzed, and the MS/MS data was again compared to the fragmentation pattern of A2E. Figure 6.8a and b present the MS/MS spectra for M+ 1,081 and 1,423, respectively. The fragmentation pattern for M+ 1,081 displayed ions with masses of
a |
1.6x105 |
|
|
||
|
1.4x105 |
|
(AU) |
1.2x105 |
|
1.0x105 |
||
Intensity |
||
6.0x104 |
||
|
8.0x104 |
|
|
4.0x104 |
|
|
2.0x104 |
|
|
0.0 |
|
b |
|
|
|
2.0x105 |
|
|
1.5x105 |
|
(AU) |
|
|
Intensity |
1.0x105 |
|
|
||
|
5.0x104 |
|
|
0.0 |
813 |
m/z 1081 |
891
|
|
|
|
|
|
825 |
|
|
|
|
|
|
|
|
799 |
|
907 |
|
1081 |
|
|
592 |
|
|
865 |
931 |
|
||
|
|
663 |
|
767 |
|
|
|||
|
487 |
|
|
|
|
|
|
||
|
|
|
|
|
|
975 |
989 |
||
|
|
|
|
|
|
|
|||
400 |
500 |
600 |
700 |
800 |
900 |
1000 |
1100 |
||
|
|
|
|
m/z |
|
|
|
|
|
|
|
757 |
|
|
|
|
1233 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
863 |
|
|
|
|
|
1424 |
|
|
|
|
|
|
|
|
|
||
|
|
795 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1249 |
|
|
1393 |
|
|
|
|
|
|
|
1317 |
|
|
591 |
|
|
|
|
1057 |
|
|
1339 |
|
|
|
|
|
|
1135 |
|
|
|
|
|
|
|
931 |
|
1019 |
|
|
|
|
600 |
|
800 |
|
1000 |
1200 |
|
1400 |
||
m/z
Fig. 6.8 (a) The MS/MS scan for M+ 1,081 located in lipofuscin. Peaks corresponding to the mass of 1,081 with the loss of 150 (m/z 931), 174 (m/z 907), and 190 (m/z 891) are identified. The mass of A2E (m/z 592) and additional peaks corresponding to smaller molecular weight compounds (m/z 813, 825, and 865) with similar losses identified in the same sample. Peaks corresponding to the mass of 1,081 with the loss if 92 (m/z 989) for toluene and the loss of 106 (m/z 975) for xylene are also identified. (b) The MS/MS results for the fragmentation of peak with M+ 1,423 in the lipofuscin sample. Peaks corresponding to the mass of 1,423 with the loss of 174 (m/z 1,249) and 190 (m/z 1,233) are identified. The mass of A2E (m/z 592) and additional peaks corresponding to smaller molecular weight compounds (m/z 757, 863, and 1,019) with similar losses identified in the same sample. Peaks corresponding to the mass of 1,423 with the loss of 92 (m/z 1,331) for toluene and the loss of 106 (m/z 1,317) for xylene are also identified
